Lantheus Holdings's revenue for the
three
months ended in Mar. 2026 was $377 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $1,546 Mil.
Lantheus Holdings's Revenue per Share for the
three
months ended in Mar. 2026 was $5.74.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $22.89.
Warning Sign:
Lantheus Holdings Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Lantheus Holdings was 7.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 19.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 34.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 8.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Lantheus Holdings's highest 3-Year average Revenue per Share Growth Rate was 50.30% per year. The lowest was -20.10% per year. And the median was -7.25% per year.
Lantheus Holdings (NAS:LNTH) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Lantheus Holdings Revenue Related Terms
Lantheus Holdings Revenue Historical Data
* Premium members only.
The historical data trend for Lantheus Holdings's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantheus Holdings Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Revenue distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,546 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings (LNTH) has a Revenue of $1,546 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Lantheus Holdings and its competitors.
Is Lantheus Holdings' Revenue too high?
Lantheus Holdings' current Revenue is $1,546 Mil. Overall, Lantheus Holdings has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' Revenue compare to LQDA and HIMS?
Lantheus Holdings' Revenue of $1,546 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Lantheus Holdings and its competitors. Lantheus Holdings's current Revenue is $1,546 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (LNTH) is currently considered Modestly Overvalued. The stock's GF Value™ is $90.70, compared to a current price of $105.69 — trading 16.5% above its estimated fair value. The current Revenue is $1,546 Mil. Lantheus Holdings' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Lantheus Holdings (LNTH), the current Revenue is $1,546 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lantheus Holdings (LNTH) Overvalued in 2026?
Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued.
The current stock price of $105.69 is trading 16.5% above its estimated GF Value™ of $90.70.
GuruFocus considers Lantheus Holdings to be Modestly Overvalued.
Key valuation signals for LNTH:
Revenue: $1,546 Mil
GF Value™: $90.70 vs. price of $105.69 (16.5% above fair value)
No single metric tells the full story. See the LNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
82GF Score
Get the complete analysis for LNTH
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LNTH has been successfully added to your 
